PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea · Delayed Price · Currency is KRW 351,500
-14,500 (-3.96%)
Sep 10, 2026, 9:15 AM KST
PharmaResearch Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,802,611 | 4,187,028 | 2,727,283 | 1,116,952 | 697,316 | 818,025 | |
Market Cap Growth | -45.78% | 53.52% | 144.17% | 60.18% | -14.76% | 48.15% |
Enterprise Value | 3,463,166 | 3,887,613 | 2,575,782 | 990,868 | 612,568 | 761,136 |
Last Close Price | 366000.00 | 403000.00 | 259933.95 | 107975.22 | 68322.03 | 79394.26 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 21.90 | 25.36 | 29.63 | 14.59 | 17.18 | 17.52 |
Forward PE | 22.16 | 23.96 | 22.06 | 12.55 | 10.92 | 14.49 |
PS Ratio | 6.30 | 7.81 | 7.79 | 4.28 | 3.58 | 5.31 |
PB Ratio | 4.82 | 5.78 | 4.78 | 2.42 | 1.88 | 2.49 |
P/TBV Ratio | 5.24 | 6.36 | 5.38 | 2.77 | 2.27 | 3.10 |
P/FCF Ratio | 27.58 | 27.29 | 26.82 | 21.12 | 16.55 | 18.32 |
P/OCF Ratio | 21.99 | 22.86 | 19.75 | 17.20 | 11.74 | 12.53 |
PEG Ratio | 0.88 | 0.48 | 0.76 | 0.32 | 0.59 | 0.54 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.74 | 7.25 | 7.36 | 3.80 | 3.15 | 4.94 |
EV/EBITDA Ratio | 14.01 | 17.04 | 18.44 | 9.50 | 8.01 | 12.27 |
EV/EBIT Ratio | 15.03 | 18.31 | 20.43 | 10.74 | 9.29 | 14.50 |
EV/FCF Ratio | 25.11 | 25.34 | 25.33 | 18.74 | 14.53 | 17.05 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.28 | 0.29 | 0.37 | 0.07 | 0.18 | 0.20 |
Debt / EBITDA Ratio | 0.87 | 0.93 | 1.49 | 0.33 | 0.87 | 1.06 |
Debt / FCF Ratio | 1.60 | 1.39 | 2.05 | 0.65 | 1.58 | 1.47 |
Net Debt / Equity Ratio | -0.47 | -0.55 | -0.40 | -0.27 | -0.32 | -0.28 |
Net Debt / EBITDA Ratio | -1.49 | -1.76 | -1.64 | -1.21 | -1.54 | -1.47 |
Net Debt / FCF Ratio | -2.72 | -2.62 | -2.25 | -2.38 | -2.79 | -2.04 |
Asset Turnover | 0.60 | 0.56 | 0.50 | 0.52 | 0.43 | 0.41 |
Inventory Turnover | 1.68 | 1.79 | 1.84 | 1.90 | 2.55 | 2.40 |
Quick Ratio | 6.61 | 6.07 | 5.84 | 2.96 | 4.04 | 3.86 |
Current Ratio | 7.78 | 6.92 | 6.75 | 3.89 | 4.56 | 4.31 |
Return on Equity (ROE) | 27.34% | 25.99% | 17.23% | 18.53% | 12.41% | 15.80% |
Return on Assets (ROA) | 14.52% | 13.97% | 11.33% | 11.38% | 9.10% | 8.78% |
Return on Invested Capital (ROIC) | 49.07% | 49.64% | 28.57% | 23.98% | 21.57% | 19.29% |
Return on Capital Employed (ROCE) | 23.40% | 22.70% | 16.30% | 19.70% | 15.60% | 13.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.88% | 3.94% | 3.38% | 6.85% | 5.82% | 5.71% |
FCF Yield | 3.63% | 3.67% | 3.73% | 4.74% | 6.04% | 5.46% |
Dividend Yield | 0.96% | 0.92% | 0.42% | 0.88% | 0.97% | 0.76% |
Payout Ratio | 23.19% | 7.10% | 10.96% | 9.84% | 15.56% | 10.77% |
Buyback Yield / Dilution | -7.09% | -12.34% | 2.50% | -5.85% | 0.76% | -5.74% |
Total Shareholder Return | -6.13% | -11.43% | 2.93% | -4.96% | 1.73% | -4.99% |